Advanced Biomed Inc. (ADVB)
| Market Cap | 9.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.37M |
| Shares Out | 21.64M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 132,321 |
| Open | 0.4800 |
| Previous Close | 0.4700 |
| Day's Range | 0.4222 - 0.4800 |
| 52-Week Range | 0.3432 - 4.1000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2025 |
About ADVB
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunost... [Read more]
Financial Performance
Financial StatementsNews
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing inno...
Sonoro Energy, Advanced BioCatalytics, and NexTier Energy Launch Strategic Collaboration to Advance Heavy Oil Recovery from Carbonate Reservoirs in the Middle East
May 5, 2025 – TheNewswire - Calgary, Alberta – Sonoro Energy Ltd. (“Sonoro” or the “Company” (TSX Venture: SNV) is pleased to announce that Sonoro, Advanced BioCatalytics Corporation, and NexTier Ener...
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering
Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and tre...
IPO Update: Advanced Biomed Finalizes $112 Million U.S. IPO Plan
Advanced Biomed has filed proposed terms for a $112 million U.S. IPO. The firm is developing a portfolio of cancer screening technologies for the Chinese market. ADVB has no revenue history, significa...
Advanced Biomed sets IPO terms, which could value the biotech at up to $625 million
Advanced Biomed Inc. ADVB, has set terms for its initial public offering, in which the Taiwan-based biotechnology company focused on treating cancer is looking to raise up to $125 million. The company...
Advanced Biomed Begins $150 Million U.S. IPO Rollout
Advanced Biomed has filed to raise $150 million in a U.S. IPO, although the final amount may vary. The Taiwan-based firm is developing various diagnostic test technologies for cancer and is focused on...
Advanced Biomed IPO Registration Document (S-1)
Advanced Biomed has filed to go public with an IPO on the NASDAQ.